Post

CiMaas to collaborate with Kiadis on NK cell development after Cytosen acquisition

On June 6 2019, Kiadis Pharma (Amsterdam, The Netherlands) acquired Cytosen (USA). CiMaas had a long-standing collaboration with Cytosen to realize production of large numbers of Natural Killer Cells. The acquisition results in that CiMaas will continue the development of the Natural Killer Cell therapy now with Kiadis. 

Post

CiMaas to present at BIO Capital Europe 2019 in Amsterdam

CiMaas will present the company at BIO Capital Europe 2019 in Amsterdam. BIO Capital Europe is a meeting place for investors and life science companies. CiMaas will present its strategy and progress  on March 14 at 5 PM.

Post

CiMaas receives ATMP classification from EMA for NK cell product

CiMaas recently applied for a classification for its’ Advanced Therapeutic Medicinal Product, adoptive NK cell therapy for multiple myeloma. Upon this request, the European Medicines Agency / Committee for Advanced Therapies considers that product NK-Xpand-MM1 falls within the definition of somatic cell therapy medicinal product, as provided in Article 2 of Regulation (EC) No 1394/2007. This… Read more »

Post

CiMaas receives second tranche of financing

Mercurius Heerlen B.V. and Werker Beleggingsmaatschappij B.V. invested a second round in CiMaas B.V. to realize cancer immunotherapy.This brings CiMaas again a step closer to fund its’ development of cellular therapies into clinical trials for the patients with multiple myeloma and lung cancer.

Post

CiMaas starts 2017 with successful first investment

MAASTRICHT, Mercurius Beleggingsmaatschappij B.V. and Werker Beleggingsmaatschappij B.V.  invest in CiMaas B.V. to realize cancer immunotherapy. CiMaas is now able to start a clinical trial in late 2017 for lung cancer patients with a cellular vaccine that will stimulate the patients’ own immune system to fight the disease.